BR112022012522A2 - Proteínas de ligação de tgf-beta-rii - Google Patents

Proteínas de ligação de tgf-beta-rii

Info

Publication number
BR112022012522A2
BR112022012522A2 BR112022012522A BR112022012522A BR112022012522A2 BR 112022012522 A2 BR112022012522 A2 BR 112022012522A2 BR 112022012522 A BR112022012522 A BR 112022012522A BR 112022012522 A BR112022012522 A BR 112022012522A BR 112022012522 A2 BR112022012522 A2 BR 112022012522A2
Authority
BR
Brazil
Prior art keywords
antibody
tgf
beta
binding proteins
antibody fragment
Prior art date
Application number
BR112022012522A
Other languages
English (en)
Inventor
Throsby Mark
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of BR112022012522A2 publication Critical patent/BR112022012522A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROTEÍNAS DE LIGAÇÃO DE TGF-BETA-RII. A presente invenção se refere a um anticorpo ou fragmento de anticorpo do mesmo que se liga especificamente ao domínio extracelular de TGF-ßRII humano. A presente invenção se refere ainda a um vetor que compreende um polinucleotídeo que codifica o anticorpo ou fragmento de anticorpo da invenção, uma célula isolada que produz o anticorpo ou fragmento de anticorpo da invenção e uma composição farmacêutica que compreende o anticorpo ou fragmento de anticorpo da invenção. O anticorpo ou fragmento de anticorpo da invenção pode ser usado para tratar câncer.
BR112022012522A 2019-12-24 2020-12-22 Proteínas de ligação de tgf-beta-rii BR112022012522A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24
PCT/NL2020/050813 WO2021133167A1 (en) 2019-12-24 2020-12-22 Tgf-beta-rii binding proteins

Publications (1)

Publication Number Publication Date
BR112022012522A2 true BR112022012522A2 (pt) 2022-09-06

Family

ID=69700252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012522A BR112022012522A2 (pt) 2019-12-24 2020-12-22 Proteínas de ligação de tgf-beta-rii

Country Status (12)

Country Link
EP (2) EP4081306A1 (pt)
JP (2) JP2023508202A (pt)
KR (2) KR20220117267A (pt)
CN (3) CN116375869A (pt)
AR (1) AR120914A1 (pt)
AU (2) AU2020412201A1 (pt)
BR (1) BR112022012522A2 (pt)
CA (1) CA3165605A1 (pt)
IL (2) IL294181A (pt)
MX (1) MX2022007919A (pt)
TW (1) TW202128747A (pt)
WO (1) WO2021133167A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127714A1 (es) * 2021-11-19 2024-02-21 Merus Nv UNIDADES DE UNIÓN MULTIESPECÍFICAS QUE COMPRENDEN LOS DOMINIOS DE UNIÓN A PD-1 Y TGF-bRII

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
EP3456190B1 (en) 2008-06-27 2021-11-24 Merus N.V. Antibody producing transgenic murine animal
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
CN103443126B (zh) 2011-01-06 2016-11-23 葛兰素集团有限公司 结合TGFβ受体II的配体
DK2900694T3 (en) 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.

Also Published As

Publication number Publication date
KR20230145542A (ko) 2023-10-17
CN116375869A (zh) 2023-07-04
AU2023200779A1 (en) 2023-03-09
JP2023076596A (ja) 2023-06-01
EP4269433A2 (en) 2023-11-01
EP4081306A1 (en) 2022-11-02
KR20220117267A (ko) 2022-08-23
IL294181A (en) 2022-08-01
AU2020412201A1 (en) 2022-07-14
CA3165605A1 (en) 2021-07-01
EP4269433A3 (en) 2024-05-22
CN115038497A (zh) 2022-09-09
JP2023508202A (ja) 2023-03-01
MX2022007919A (es) 2022-07-27
IL304317A (en) 2023-09-01
AR120914A1 (es) 2022-03-30
WO2021133167A1 (en) 2021-07-01
TW202128747A (zh) 2021-08-01
CN116199780A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
BR112019010943A8 (pt) Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
BR112018070998A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes
BR112018001374A2 (pt) construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112018001531A2 (pt) construtos de anticorpo para cd70 e cd3
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112018068340A2 (pt) imunoglobulinas de ligação ao tgfss1 e usos destas
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
BR112016002199B8 (pt) Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BR112017022326A2 (pt) construções de anticorpo biespecífico para cdh3 e cd3
BR112018007318A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição.
BR112017002703A2 (pt) anticorpos específicos de mmp9.
BR112021013397A2 (pt) Anticorpos anti-tigit

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023027661-2 PROTOCOLO 870230114727 EM 28/12/2023 11:23.